Syeda Rizvi, MD
Geriatric Medicine · Seminole, FLNPI 1669671913
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 170 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Among geriatric medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 170 payments — averaging $18.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$597
- AstraZeneca$371
- Pfizer$222
- Amarin Pharma, Inc.$206
- Lilly USA, LLC$180
- Phathom Pharmaceuticals, Inc.$176
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,227100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 36 | $597 |
| AstraZeneca | 21 | $371 |
| Pfizer | 13 | $222 |
| Amarin Pharma, Inc. | 11 | $206 |
| Lilly USA, LLC | 9 | $180 |
| Phathom Pharmaceuticals, Inc. | 2 | $176 |
| Johnson & Johnson(2 entities) | 10 | $173 |
| Novartis | 10 | $170 |
| Amgen | 10 | $160 |
| AbbVie | 6 | $158 |
| Sanofi-aventis U.S. LLC | 6 | $117 |
| Boehringer Ingelheim | 6 | $116 |
| Lundbeck LLC | 4 | $85 |
| Abbott | 4 | $72 |
| Novo Nordisk | 3 | $62 |
| Astellas Pharma US Inc | 3 | $56 |
| E.r. Squibb & Sons, L.L.C. | 4 | $55 |
| Otsuka America Pharmaceutical, Inc. | 2 | $50 |
| Merck | 2 | $41 |
| Bayer | 2 | $37 |
| Sanofi | 1 | $31 |
| Arbor Pharmaceuticals, Inc. | 1 | $27 |
| Dexcom, Inc. | 1 | $24 |
| Si-bone, Inc. | 1 | $14 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
How this compares
$3,227 in reported general payments places this provider in the 90th percentile of 305 geriatric medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 171 | $171,864 |
| OzempicSemaglutide | 129 | $155,094 |
| FarxigaDapagliflozin Propanediol | 71 | $66,436 |
| XareltoRivaroxaban | 54 | $52,920 |
| JanuviaSitagliptin Phosphate | 32 | $46,889 |
| JardianceEmpagliflozin | 36 | $41,636 |
| MounjaroTirzepatide | 32 | $31,530 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $24,975 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $19,203 |
| Celecoxib | 171 | $19,047 |
| EntrestoSacubitril/Valsartan | 21 | $18,686 |
| Spiriva RespimatTiotropium Bromide | 22 | $17,626 |
| LinzessLinaclotide | 20 | $17,432 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $16,614 |
| Modafinil | 35 | $14,140 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $222 | $171,864171 claims |
| Novo NordiskOzempic, Rybelsus | $62 | $166,532141 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $371 | $86,15094 claims |
| MerckJanuvia, Janumet | $41 | $63,50343 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $116 | $59,26258 claims |
| Johnson & JohnsonXarelto | $173 | $52,92054 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $597 | $44,17842 claims |
| AbbVieLinzess, Restasis, Synthroid | $158 | $37,505120 claims |
| Lilly USA, LLCMounjaro | $180 | $31,53032 claims |
| NovartisEntresto | $170 | $18,68621 claims |
| Astellas Pharma US IncMyrbetriq | $56 | $8,60114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 305 geriatric medicine providers in Florida.
Other geriatric medicine in Seminole
- Malcolm FraserBrooksville$359K
- Andrew ScanameoTallahassee$172K
- Naushira PandyaDavie$145K
- Rosemary LairdViera$64K
- Jonathan AppelbaumMonticello$59K
- John PotomskiMelbourne$31K
- Valeria Baldivieso HurtadoWinter Park$28K
- Kae FerberNaples$18K
- Stuti DangMiami$17K
- Angel HerreraNaples$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.